Target intelligence / Profile preview

POU3F3 adjacent non-coding transcript 1 (PANTR1)

Target
PANTR1
Molecular classification
Long non-coding RNA (lncRNA), RNA, long non-coding
01

Overview

POU3F3 adjacent non-coding transcript 1 (PANTR1) is a long non-coding RNA gene (lncRNA), highly conserved between human and mouse, which modulates the site-specific chromatin binding of transcription factors such as FOXG1 and NEUROD1 during neuronal development. PANTR1 is transcriptionally regulated by FOXG1 and, in turn, governs FOXG1’s localization at select genome regions, thereby influencing the epigenetic landscape and neuronal differentiation. Although synonyms suggest possible relevance in cancer, its best-documented and canonical role is as a neural regulator, contributing mechanistically to FOXG1-syndrome and neuronal outgrowth. There are no drugs or small molecules known to target PANTR1 directly, and it is not considered a classical "therapeutic target" but rather a biological modulator of cell phenotype.

Other names
LINC-BRN1ALINC-POU3F3LINC01114LINC01158linc-Brn1alinc-POU3F3long intergenic non-protein coding RNA 1114long intergenic non-protein coding RNA 1158PANTR1PANCATpancreatic cancer associated transcript
02

Mechanism of action

not applicable

03

Biological functions

Chromatin binding regulation (modulates FOXG1 binding at specific genomic loci)Regulation of gene expression and neuronal differentiationMediates site-directed recruitment of transcription factors (such as FOXG1 and NEUROD1)
04

Disease associations

Neurodevelopmental disorders (FOXG1-syndrome)Potential roles in cancer, based on alternative naming and selected transcript aliases, but currently most evidence is for neural regulation
05

Safety considerations

None documented specifically for PANTR1; therapeutic manipulation of lncRNAs in general carries risks of off-target effects, immune activation, and delivery challenges, but these are generic
06

Biomarkers

PANTR1 itself is proposed as a regulatory biomarker for neuronal differentiation (by its activity in FOXG1-syndrome); possible biomarker status in cancer inferred from some aliases, but not substantiated in contemporary clinical literature

Beyond the preview

Go deeper on POU3F3 adjacent non-coding transcript 1 (PANTR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on POU3F3 adjacent non-coding transcript 1 (PANTR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call